Caris Life Sciences (NASDAQ:CAI) Shares Gap Down - What's Next?

Key Points

• Shares plunged: Caris Life Sciences opened at $27.18, down from the prior close of $33.22, and last traded near $26.75.
• Revenue and outlook grew: Third-quarter revenue rose 27% year over year to $275.4 million, and the company raised its 2026 revenue guidance to $1.04–$1.05 billion. Adjusted EPS of $0.05 beat estimates but was below $0.08 a year earlier, while net income fell 37%.
• Analyst sentiment remains generally positive: The stock has a “Moderate Buy” consensus rating and an average price target of $29.91, though ratings include five Holds and one Sell alongside eight Buys.

Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report)'s stock price gapped down before the market opened on Thursday. The stock had previously closed at $33.22, but opened at $27.18. Caris Life Sciences shares last traded at $26.7540, with a volume of 1,211,277 shares traded.

Key Stories Impacting Caris Life Sciences

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Third-quarter revenue rose 27% year over year to $275.4 million, driven by molecular profiling services. Caris raised its 2026 revenue guidance to $1.04–$1.05 billion, implying 28%–29% growth. Caris Q3 results and guidance
• Positive Sentiment: Adjusted earnings of $0.05 per share beat the $0.03 consensus estimate, though they were below the $0.08 reported a year earlier. Q3 earnings and revenue estimates
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and $38 price target, which the report described as 45.5% above the then-current share price. BTIG Research rating
• Negative Sentiment: Net income fell 37% year over year as expenses increased. The earnings-per-share decline versus last year may temper enthusiasm about the revenue growth and raised outlook. Q3 income and outlook report

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CAI. Wall Street Zen raised Caris Life Sciences from a "sell" rating to a "hold" rating in a report on Sunday, August 16th. Canaccord Genuity Group increased their target price on shares of Caris Life Sciences from $22.00 to $30.00 and gave the stock a "hold" rating in a research note on Monday, October 19th. Weiss Ratings downgraded shares of Caris Life Sciences from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, October 2nd. TD Cowen restated a "buy" rating on shares of Caris Life Sciences in a research report on Thursday. Finally, BTIG Research reaffirmed a "buy" rating and issued a $38.00 price target on shares of Caris Life Sciences in a report on Thursday. Eight investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $29.91.

Caris Life Sciences Price Performance

The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66. The business's 50-day simple moving average is $29.52 and its 200 day simple moving average is $21.74. The firm has a market capitalization of $7.37 billion, a P/E ratio of 72.65 and a beta of 0.71.

Caris Life Sciences (NASDAQ:CAI - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.02. The company had revenue of $275.36 million during the quarter. Caris Life Sciences had a net margin of 10.62% and a return on equity of 18.77%. Caris Life Sciences's revenue for the quarter was up 27.0% on a year-over-year basis. During the same period last year, the company posted $0.08 EPS. Sell-side analysts forecast that Caris Life Sciences, Inc. will post 0.13 earnings per share for the current year.

Insider Activity at Caris Life Sciences

In other Caris Life Sciences news, President David Spetzler sold 119,212 shares of the business's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $24.76, for a total value of $2,951,689.12. Following the completion of the sale, the president owned 1,182,871 shares in the company, valued at approximately $29,287,885.96. The trade was a 9.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Russel Denton sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $31.82, for a total value of $238,650.00. Following the sale, the insider directly owned 174,855 shares of the company's stock, valued at approximately $5,563,886.10. This trade represents a 4.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,004,712 shares of company stock worth $27,205,419 in the last ninety days. 50.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Caris Life Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Lido Advisors LLC purchased a new position in Caris Life Sciences in the third quarter worth about $790,000. AlphaCore Capital LLC bought a new stake in shares of Caris Life Sciences during the 3rd quarter valued at about $360,000. Fulcrum Asset Management LLP purchased a new stake in shares of Caris Life Sciences during the 3rd quarter valued at about $948,000. Brighton Jones LLC purchased a new stake in shares of Caris Life Sciences during the 3rd quarter valued at about $1,161,000. Finally, Pictet Asset Management Holding SA bought a new position in shares of Caris Life Sciences in the 3rd quarter worth approximately $425,000.

Caris Life Sciences Company Profile

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient's disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.